Navigation Links
Gen-Probe to Webcast Three Upcoming Investor Presentations
Date:2/24/2011

SAN DIEGO, Feb. 24, 2011 /PRNewswire/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at three upcoming investor conferences:

  • RBC Capital Markets' Healthcare Conference in New York at 10 a.m. Eastern Time (ET) on March 2.  The Company also will participate in a panel discussion entitled The Future of Molecular Testing at 3:35 p.m. ET the same day.
  • Cowen and Company's 31st Annual Healthcare Conference in Boston at 10:15 a.m. ET on March 9.
  • Barclays Capital's 2011 Global Healthcare Conference in Miami at 3:15 p.m. ET on March 16.

  • The presentations and the panel discussion will be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com.  The webcasts will be available for 30 days following the events.

    About Gen-ProbeGen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

    Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-K, and all subsequent periodic filings.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.Contact:Paula IzidoroInvestor Relations858-410-8904
    '/>"/>

    SOURCE Gen-Probe Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
    2. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
    3. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
    4. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
    5. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
    6. Gen-Probe to Webcast Two Upcoming Investor Presentations
    7. Neogen Acquires Gen-Probes BioKits Food Safety Business
    8. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
    9. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
    10. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
    11. Gen-Probe to Webcast Two Upcoming Investor Presentations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
    (Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
    (Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
    Breaking Medicine Technology:
    (Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies ... to help with process innovation in drug formulation and manufacturing. CoreRx offers ... state-of-the-art analytical equipment in support of their development and manufacturing goals. , ...
    (Date:4/25/2017)... Atlanta, GA (PRWEB) , ... April 25, 2017 , ... ... to their neck and back pain with a reputable physician in their area, announces ... The CRM protects patient information for patients who are looking for reputable physicians to ...
    (Date:4/25/2017)... ... ... Chaudhary, MD is committed to providing the highest quality of spine care to all his ... with all my patients to alleviate possible future issues. I am pleased to have you ... and my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary ...
    (Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished ... the Outlier Leadership Series, Outliers in Writing, set to publish in summer 2017. ... Medicine at the University of Arizona College of Medicine. He also serves as Medical ...
    (Date:4/25/2017)... ... April 25, 2017 , ... ... products, is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s ... health in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports ...
    Breaking Medicine News(10 mins):